CEO Salary & Executive Compensation
Gilead Sciences GILD
CEO: Daniel O'Day · Biotechnology · 17,000 employees
Daniel O'Day, CEO of Gilead Sciences (GILD), earned $12.0M in total compensation in 2025. Gilead Sciences receives a Pay-for-Performance grade of B (70/100), with a CEO-to-worker pay ratio of 96:1 and a say-on-pay shareholder approval of 87.0%. The company's 3-year total shareholder return is +12.4%.
How Gilead Sciences CEO Pay Compares
Daniel O'Day's $12.0M total compensation is 0% below the Biotechnology industry median of $12.0M. The 96:1 CEO-to-worker pay ratio is 4% higher than the industry average of 92:1.
Gilead Sciences (GILD) disclosed $12.0M in CEO compensation for Daniel O'Day. The package is structured for retention plus performance alignment, with equity awards taking the largest share.
The CEO-to-median-worker pay ratio runs 96x. Lower ratios typically reflect companies with higher-paid workforces (financial services, technology, professional services) where the median worker pay denominator is itself substantial. Three-year performance has been roughly flat — TSR of 12.4% alongside 5.6% revenue growth. Flat performance over a multi-year window is where pay-versus-performance debates get the most heated: large compensation packages without commensurate shareholder returns are the modal complaint at annual meetings.
Shareholders supported the compensation package at 87% on the most recent say-on-pay vote. Solid support without overwhelming endorsement is the typical pattern for established public companies with conventional compensation programs. Gilead Sciences operates in Biotechnology with 17,000 employees and $27.1B in annual revenue, and currently carries a market capitalization of $120.0B. Pay comparisons across companies require controlling for these structural factors — a $20M package at a $10B-revenue tech company reads differently than the same package at a $1B-revenue industrial.
Source: SEC EDGAR — DEF 14A proxy statements for Gilead Sciences (GILD).
Compensation Breakdown
Daniel O'Day's $12.0M total compensation package for fiscal year 2025 includes $1.2M in base salary, $6.0M in stock awards, $1.4M in option awards, and $1.8M in bonus and non-equity incentives.
Compensation History
| Year | Salary | Bonus | Stock Awards | Options | Non-Equity | Other | Total |
|---|---|---|---|---|---|---|---|
| 2025 | $1.2M | - | $6.0M | $1.4M | $1.8M | $1.3M | $12.0M |
| 2024 | $1.2M | - | $6.0M | $1.4M | $1.8M | $1.3M | $12.0M |
| 2023 | $1.2M | - | $6.0M | $1.4M | $1.8M | $1.3M | $12.0M |
| 2022 | $1.2M | - | $6.0M | $1.4M | $1.8M | $1.3M | $12.0M |
All compensation data is sourced from SEC DEF 14A proxy filings submitted to EDGAR. The Economic Policy Institute's CEO pay analysis provides additional context on executive compensation trends across industries.
Named Executive Officers
Peer CEO Compensation
Daniel O'Day, CEO of Gilead Sciences (GILD), earns $12.0M in total compensation. This includes base salary, stock awards, option awards, and other incentives as reported in the company's most recent DEF 14A proxy statement.
Frequently Asked Questions
Daniel O'Day, CEO of Gilead Sciences (GILD), earns $12.0M in total compensation. This includes base salary, stock awards, option awards, and other incentives as reported in the company's most recent DEF 14A proxy statement.
Gilead Sciences has a Pay-for-Performance Score of B (70/100). The company's 3-year total shareholder return is +12.4%, and the say-on-pay shareholder vote passed with 87.0% approval.
The CEO-to-median-worker pay ratio at Gilead Sciences is 96:1. The median worker at Gilead Sciences earns $125K per year, while CEO Daniel O'Day earns $12.0M in total compensation.
Gilead Sciences employs approximately 17,000 people. The company operates in the Biotechnology industry within the Healthcare sector, generating $27.1B in annual revenue.